APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multi-cancer Early Detection (MCED) Tests

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multi-cancer Early Detection (MCED) Tests Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchMulti-cancer Early Detection (MCED) Tests Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Multi-cancer Early Detection (MCED) Tests Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Multi-cancer Early Detection (MCED) Tests Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multi-cancer Early Detection (MCED) Tests Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Multi-cancer Early Detection (MCED) Tests Market Analysis and Forecast 2026-2032239 pages · $4,950 USD

Market perspective

The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multi-cancer Early Detection (MCED) Tests is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multi-cancer Early Detection (MCED) Tests is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multi-cancer Early Detection (MCED) Tests is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multi-cancer Early Detection (MCED) Tests market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multi-cancer Early Detection (MCED) Tests market include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Multi-cancer Early Detection (MCED) Tests market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multi-cancer Early Detection (MCED) Tests and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multi-cancer Early Detection (MCED) Tests revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Multi-cancer Early Detection (MCED) Tests market.

Multi-cancer Early Detection (MCED) Tests Segment by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

Surexam Bio-Tech Co.,Ltd.

HaploX

HefeiLaierBiotechnologyCo.,Ltd

Multi-cancer Early Detection (MCED) Tests Segment by Type

ctDNA Detection

CTC Detection

Exosome Detection

Multi-cancer Early Detection (MCED) Tests Segment by Application

Medical Institutions

Physical Examination Centers

Multi-cancer Early Detection (MCED) Tests Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multi-cancer Early Detection (MCED) Tests status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Multi-cancer Early Detection (MCED) Tests key companies, revenue, market share, and recent developments.

3. To split the Multi-cancer Early Detection (MCED) Tests breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Multi-cancer Early Detection (MCED) Tests market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multi-cancer Early Detection (MCED) Tests significant trends, drivers, influence factors in global and regions.

6. To analyze Multi-cancer Early Detection (MCED) Tests competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-cancer Early Detection (MCED) Tests market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multi-cancer Early Detection (MCED) Tests and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-cancer Early Detection (MCED) Tests.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multi-cancer Early Detection (MCED) Tests industry.

Chapter 3: Detailed analysis of Multi-cancer Early Detection (MCED) Tests company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Multi-cancer Early Detection (MCED) Tests in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Multi-cancer Early Detection (MCED) Tests in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multi-cancer Early Detection (MCED) Tests Industry Trends Table 2. Multi-cancer Early Detection (MCED) Tests Industry Drivers Table 3. Multi-cancer Early Detection (MCED) Tests Industry Opportunities and Challenges Table 4. Multi-cancer Early Detection (MCED) Tests Industry Restraints Table 5. Global Multi-cancer Early Detection (MCED) Tests Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multi-cancer Early Detection (MCED) Tests Revenue Share by Company (2021-2026) Table 7. Global Multi-cancer Early Detection (MCED) Tests Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Multi-cancer Early Detection (MCED) Tests Key Company Manufacturing Base & Headquarters Table 9. Global Multi-cancer Early Detection (MCED) Tests Company, Product Type & Application Table 10. Global Multi-cancer Early Detection (MCED) Tests Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Multi-cancer Early Detection (MCED) Tests by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ctDNA Detection Table 15. Significant Companies of CTC Detection Table 16. Significant Companies of Exosome Detection Table 17. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type (2021-2026) Table 21. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Medical Institutions Table 23. Significant Companies of Physical Examination Centers Table 24. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application (2021-2026) Table 28. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application (2027-2032) Table 29. Global Multi-cancer Early Detection (MCED) Tests Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Region (2021-2026) Table 32. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Region (2027-2032) Table 34. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Multi-cancer Early Detection (MCED) Tests Sales Value Market Share by Country (2021-2026) Table 37. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Multi-cancer Early Detection (MCED) Tests Sales Value Market Share by Country (2027-2032) Table 39. Guardant Health Company Information Table 40. Guardant Health Business Overview Table 41. Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 43. Guardant Health Recent Development Table 44. Exact Sciences Company Information Table 45. Exact Sciences Business Overview Table 46. Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 48. Exact Sciences Recent Development Table 49. Freenome Company Information Table 50. Freenome Business Overview Table 51. Freenome Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 53. Freenome Recent Development Table 54. Epiginomics AG Company Information Table 55. Epiginomics AG Business Overview Table 56. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 58. Epiginomics AG Recent Development Table 59. Bio-techne Company Information Table 60. Bio-techne Business Overview Table 61. Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 63. Bio-techne Recent Development Table 64. ThriveEarlier Detection Company Information Table 65. ThriveEarlier Detection Business Overview Table 66. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 68. ThriveEarlier Detection Recent Development Table 69. GRAIL, Inc. Company Information Table 70. GRAIL, Inc. Business Overview Table 71. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 73. GRAIL, Inc. Recent Development Table 74. CellMax life Company Information Table 75. CellMax life Business Overview Table 76. CellMax life Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 78. CellMax life Recent Development Table 79. Berry Genomics Company Information Table 80. Berry Genomics Business Overview Table 81. Berry Genomics Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 83. Berry Genomics Recent Development Table 84. Singlera Genomics Company Information Table 85. Singlera Genomics Business Overview Table 86. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 88. Singlera Genomics Recent Development Table 89. Geneseeq Company Information Table 90. Geneseeq Business Overview Table 91. Geneseeq Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 93. Geneseeq Recent Development Table 94. BGI Genomics Company Information Table 95. BGI Genomics Business Overview Table 96. BGI Genomics Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 98. BGI Genomics Recent Development Table 99. Burning Rock Biotech Limited Company Information Table 100. Burning Rock Biotech Limited Business Overview Table 101. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 103. Burning Rock Biotech Limited Recent Development Table 104. New Horizon Health Limited Company Information Table 105. New Horizon Health Limited Business Overview Table 106. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 108. New Horizon Health Limited Recent Development Table 109. Yeasen Bio Company Information Table 110. Yeasen Bio Business Overview Table 111. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 113. Yeasen Bio Recent Development Table 114. Hangzhou Aoru Biotech Company Information Table 115. Hangzhou Aoru Biotech Business Overview Table 116. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 118. Hangzhou Aoru Biotech Recent Development Table 119. Amoy Diagnostics Co., Ltd. Company Information Table 120. Amoy Diagnostics Co., Ltd. Business Overview Table 121. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 123. Amoy Diagnostics Co., Ltd. Recent Development Table 124. Genetron Health Company Information Table 125. Genetron Health Business Overview Table 126. Genetron Health Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 128. Genetron Health Recent Development Table 129. AnchorDx Company Information Table 130. AnchorDx Business Overview Table 131. AnchorDx Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 133. AnchorDx Recent Development Table 134. Surexam Bio-Tech Co.,Ltd. Company Information Table 135. Surexam Bio-Tech Co.,Ltd. Business Overview Table 136. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 138. Surexam Bio-Tech Co.,Ltd. Recent Development Table 139. HaploX Company Information Table 140. HaploX Business Overview Table 141. HaploX Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 143. HaploX Recent Development Table 144. HefeiLaierBiotechnologyCo.,Ltd Company Information Table 145. HefeiLaierBiotechnologyCo.,Ltd Business Overview Table 146. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 147. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 148. HefeiLaierBiotechnologyCo.,Ltd Recent Development Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Multi-cancer Early Detection (MCED) Tests Product Image Figure 2. Global Multi-cancer Early Detection (MCED) Tests Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032) & (US$ Million) Figure 4. Global Multi-cancer Early Detection (MCED) Tests Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ctDNA Detection Image Figure 8. CTC Detection Image Figure 9. Exosome Detection Image Figure 10. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type (2021-2032) Figure 13. Medical Institutions Image Figure 14. Physical Examination Centers Image Figure 15. Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application (2021-2032) Figure 18. Global Multi-cancer Early Detection (MCED) Tests Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032) & (US$ Million) Figure 21. North America Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032) & (US$ Million) Figure 27. South America Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • ctDNA Detection
  • CTC Detection
  • Exosome Detection
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx
  • Surexam Bio-Tech Co.,Ltd.
  • HaploX
  • HefeiLaierBiotechnologyCo.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multi-cancer Early Detection (MCED) Tests Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Multi-cancer Early Detection (MCED) Tests Market Dynamics
  1. 2.1 Multi-cancer Early Detection (MCED) Tests Industry Trends
  2. 2.2 Multi-cancer Early Detection (MCED) Tests Industry Drivers
  3. 2.3 Multi-cancer Early Detection (MCED) Tests Industry Opportunities and Challenges
  4. 2.4 Multi-cancer Early Detection (MCED) Tests Industry Restraints
3 Multi-cancer Early Detection (MCED) Tests Market by Company
  1. 3.1 Global Multi-cancer Early Detection (MCED) Tests Company Revenue Ranking in 2025
  2. 3.2 Global Multi-cancer Early Detection (MCED) Tests Revenue by Company (2021-2026)
  3. 3.3 Global Multi-cancer Early Detection (MCED) Tests Company Ranking (2024-2026)
  4. 3.4 Global Multi-cancer Early Detection (MCED) Tests Company Manufacturing Base and Headquarters
  5. 3.5 Global Multi-cancer Early Detection (MCED) Tests Company Product Type and Application
  6. 3.6 Global Multi-cancer Early Detection (MCED) Tests Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Multi-cancer Early Detection (MCED) Tests Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Multi-cancer Early Detection (MCED) Tests Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Multi-cancer Early Detection (MCED) Tests Market by Type
  1. 4.1 Multi-cancer Early Detection (MCED) Tests Type Introduction
  2. 4.1.1 ctDNA Detection
  3. 4.1.2 CTC Detection
  4. 4.1.3 Exosome Detection
  5. 4.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type
  6. 4.2.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Type (2021-2032)
  8. 4.2.3 Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type (2021-2032)
5 Multi-cancer Early Detection (MCED) Tests Market by Application
  1. 5.1 Multi-cancer Early Detection (MCED) Tests Application Introduction
  2. 5.1.1 Medical Institutions
  3. 5.1.2 Physical Examination Centers
  4. 5.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application
  5. 5.2.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Application (2021-2032)
  7. 5.2.3 Global Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application (2021-2032)
6 Multi-cancer Early Detection (MCED) Tests Regional Value Analysis
  1. 6.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region (2021-2032)
  3. 6.2.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region: 2021-2026
  4. 6.2.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032)
  7. 6.3.2 North America Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032)
  10. 6.4.2 Europe Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032)
  16. 6.6.2 South America Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Sales Value Share by Country, 2025 VS 2032
7 Multi-cancer Early Detection (MCED) Tests Country-level Value Analysis
  1. 7.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country (2021-2032)
  3. 7.2.1 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country (2021-2026)
  4. 7.2.2 Global Multi-cancer Early Detection (MCED) Tests Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Multi-cancer Early Detection (MCED) Tests Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Guardant Health
  2. 8.1.1 Guardant Health Company Information
  3. 8.1.2 Guardant Health Business Overview
  4. 8.1.3 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  6. 8.1.5 Guardant Health Recent Developments
  7. 8.2 Exact Sciences
  8. 8.2.1 Exact Sciences Company Information
  9. 8.2.2 Exact Sciences Business Overview
  10. 8.2.3 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio
  12. 8.2.5 Exact Sciences Recent Developments
  13. 8.3 Freenome
  14. 8.3.1 Freenome Company Information
  15. 8.3.2 Freenome Business Overview
  16. 8.3.3 Freenome Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio
  18. 8.3.5 Freenome Recent Developments
  19. 8.4 Epiginomics AG
  20. 8.4.1 Epiginomics AG Company Information
  21. 8.4.2 Epiginomics AG Business Overview
  22. 8.4.3 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio
  24. 8.4.5 Epiginomics AG Recent Developments
  25. 8.5 Bio-techne
  26. 8.5.1 Bio-techne Company Information
  27. 8.5.2 Bio-techne Business Overview
  28. 8.5.3 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio
  30. 8.5.5 Bio-techne Recent Developments
  31. 8.6 ThriveEarlier Detection
  32. 8.6.1 ThriveEarlier Detection Company Information
  33. 8.6.2 ThriveEarlier Detection Business Overview
  34. 8.6.3 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio
  36. 8.6.5 ThriveEarlier Detection Recent Developments
  37. 8.7 GRAIL, Inc.
  38. 8.7.1 GRAIL, Inc. Company Information
  39. 8.7.2 GRAIL, Inc. Business Overview
  40. 8.7.3 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  42. 8.7.5 GRAIL, Inc. Recent Developments
  43. 8.8 CellMax life
  44. 8.8.1 CellMax life Company Information
  45. 8.8.2 CellMax life Business Overview
  46. 8.8.3 CellMax life Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio
  48. 8.8.5 CellMax life Recent Developments
  49. 8.9 Berry Genomics
  50. 8.9.1 Berry Genomics Company Information
  51. 8.9.2 Berry Genomics Business Overview
  52. 8.9.3 Berry Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  54. 8.9.5 Berry Genomics Recent Developments
  55. 8.10 Singlera Genomics
  56. 8.10.1 Singlera Genomics Company Information
  57. 8.10.2 Singlera Genomics Business Overview
  58. 8.10.3 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  60. 8.10.5 Singlera Genomics Recent Developments
  61. 8.11 Geneseeq
  62. 8.11.1 Geneseeq Company Information
  63. 8.11.2 Geneseeq Business Overview
  64. 8.11.3 Geneseeq Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio
  66. 8.11.5 Geneseeq Recent Developments
  67. 8.12 BGI Genomics
  68. 8.12.1 BGI Genomics Company Information
  69. 8.12.2 BGI Genomics Business Overview
  70. 8.12.3 BGI Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  72. 8.12.5 BGI Genomics Recent Developments
  73. 8.13 Burning Rock Biotech Limited
  74. 8.13.1 Burning Rock Biotech Limited Company Information
  75. 8.13.2 Burning Rock Biotech Limited Business Overview
  76. 8.13.3 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  78. 8.13.5 Burning Rock Biotech Limited Recent Developments
  79. 8.14 New Horizon Health Limited
  80. 8.14.1 New Horizon Health Limited Company Information
  81. 8.14.2 New Horizon Health Limited Business Overview
  82. 8.14.3 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  83. 8.14.4 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  84. 8.14.5 New Horizon Health Limited Recent Developments
  85. 8.15 Yeasen Bio
  86. 8.15.1 Yeasen Bio Company Information
  87. 8.15.2 Yeasen Bio Business Overview
  88. 8.15.3 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio
  90. 8.15.5 Yeasen Bio Recent Developments
  91. 8.16 Hangzhou Aoru Biotech
  92. 8.16.1 Hangzhou Aoru Biotech Company Information
  93. 8.16.2 Hangzhou Aoru Biotech Business Overview
  94. 8.16.3 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio
  96. 8.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 8.17 Amoy Diagnostics Co., Ltd.
  98. 8.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 8.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 8.17.3 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  102. 8.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 8.18 Genetron Health
  104. 8.18.1 Genetron Health Company Information
  105. 8.18.2 Genetron Health Business Overview
  106. 8.18.3 Genetron Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  108. 8.18.5 Genetron Health Recent Developments
  109. 8.19 AnchorDx
  110. 8.19.1 AnchorDx Company Information
  111. 8.19.2 AnchorDx Business Overview
  112. 8.19.3 AnchorDx Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio
  114. 8.19.5 AnchorDx Recent Developments
  115. 8.20 Surexam Bio-Tech Co.,Ltd.
  116. 8.20.1 Surexam Bio-Tech Co.,Ltd. Company Information
  117. 8.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
  118. 8.20.3 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  120. 8.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
  121. 8.21 HaploX
  122. 8.21.1 HaploX Company Information
  123. 8.21.2 HaploX Business Overview
  124. 8.21.3 HaploX Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  125. 8.21.4 HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio
  126. 8.21.5 HaploX Recent Developments
  127. 8.22 HefeiLaierBiotechnologyCo.,Ltd
  128. 8.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Information
  129. 8.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
  130. 8.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  131. 8.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio
  132. 8.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst